Tyroserleutide

Tripeptide / Antitumor PeptideRx: InvestigationalCompound: Investigational

Also known as: H-Tyr-Ser-Leu-OH, Tyr-Ser-Leu, Tyrosine-Serine-Leucine, YSL

Educational Only — Not medical advice. Consult a qualified clinician before using any peptide.

Summary

Tyroserleutide (YSL) is a synthetic tripeptide originally derived from thymosin with demonstrated antitumor activity in preclinical and early clinical studies, particularly for hepatocellular carcinoma (HCC). It has been investigated as an adjunct to surgery or chemotherapy in liver cancer patients in China, showing potential to inhibit tumor recurrence and metastasis.

Mechanism of Action

Tyroserleutide (YSL) is a tripeptide (Tyr-Ser-Leu) derived from thymosin that inhibits tumor cell proliferation and induces apoptosis. It modulates protein kinase C (PKC) activity, suppresses tumor angiogenesis, inhibits DNA synthesis in cancer cells, and may enhance immune function by modulating T-lymphocyte activity.

Routes of Administration

IntramuscularIntravenousSubcutaneous

Goals & Uses

  • Anti-angiogenic activityOncologyLow
  • Inhibition of tumor metastasisOncologyLow
  • Inhibition of hepatocellular carcinoma recurrence post-resectionOncologyModerate
  • Tumor cell apoptosis inductionOncologyModerate
  • Immune modulationImmunologyLow

Contraindications

  • Severe hepatic or renal impairmentOrgan ImpairmentModerate
  • Known hypersensitivity to tyroserleutide or any component of the formulationAllergyHigh
  • PregnancyPopulationHighPotential fetal risk or insufficient safety data

Adverse Effects

  • Allergic reactionsImmunologicalRare
  • Fever / mild pyrexiaSystemicUncommon
  • Injection site reactionsLocalCommon
  • Gastrointestinal discomfortGastrointestinalUncommon

Drug Interactions

  • Chemotherapeutic agents (e.g., cisplatin, 5-FU)Low
  • ImmunosuppressantsModeratePotential interaction with immune pathways or infection risk

Population Constraints

  • Pediatric patientsAgeRelative
  • Lactating womenReproductiveRelative
  • Pregnant womenReproductiveRelative

Regulatory Status

  • European UnionUnapprovedNot approved by the EMA; no marketing authorization granted.
  • United StatesInvestigationalNot approved by the FDA; no active IND publicly listed as of knowledge cutoff.
  • United KingdomUnapprovedNot approved by the MHRA.

Tyroserleutide has been investigated primarily in China for hepatocellular carcinoma. It has received investigational status and has undergone clinical trials in China. It is not approved by the FDA or EMA as of the current knowledge cutoff.

Evidence & Sources

No sources recorded yet.

Browse All PeptidesBuild My Stack